3-Amino-4-Fluorophenol

62257-16-3

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient♦ed and realizes industrial development through R&D innovation and techno‍logy transformation.

key word:

Pharmaceutical technology

Category:

Consulting
Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strivesλ to build a large health industry finance platform company integrating pharmaceutical, in×telligent medical, bio pharmaceutical R&D, industrial productio n and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitratio n reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlori¥nation reaction, bromination reaction, diazotization reaction, format↔ reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In O≤ctober 2006, Sitagliptin phosphate Januvia was approved by FDA‌ as the first DPP4 inhibitor for the treatment of type ⅱ diab∏etes mellitus. The characteristics of this drug are that it can♦ stimulate insulin secretion while reducing hunger without causing weight πgain. Hypoglycemia and edema will not occur, and it is suitable for diabetic p₽atients with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri∞se that is market-oriented and realizes industrial develo₩pment through R&D innovation and technology transformation∏.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is§ one of the most important products for the treatment of arthritis. It is well tolerated εand has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonist✔s. In clinical application, it has good therapeutic effect on atopic asthma a±nd other types of bronchial asthma, and the market prospect is huge. In the ∞major category of asthma drugs, leukotriene receptor antagonists have the fastest growing marke>t share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprisλe that is market-oriented and realizes industrial development through R&D innovation and technolo∞gy transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome♥. It is the second drug approved by FDA for Alzheimer's disease in the United States. Its tre♠atment reaches the target dose and has low toxic and side effects. It has been widely recogni®zed by our medical community, and good tolerance is its  biggest advantage. In October 1999, Donepezil was launched in China under t he trade name "Aricept", which is the main chemical drug against Alzheimer's disease. At present , CFDA has approved a number of domestic enterprises to prod'uce donepezil preparations, the main dosage forms are tablets, capsules, dispersive table≈ts, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfi₩zer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member sta€tes. The world's first drug approved to prevent venous thromboembolism (VT≠E) in adult patients undergoing elective hip or knee replacement. From June 2019 to June 2020, ↔the annual sales of apixaban products overseas reached about $15.4 billion, with a year-on-ye₹ar growth of nearly 32%, and the API consumption reached about 23,960 kg, with a >year-on-year growth of about 28%. Compared with its main competitor,÷ Rivaroxaban, the drug's annual overseas sales are aboutσ $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri↑se that is market-oriented and realizes industrial development through R&D innovation ‌and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme↔. On December 29, 2004, it was approved by FDA for the treatment of refractory or relapsed ∏acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is Ωmarket-oriented and realizes industrial development through R&D innovation♠ and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If y≥ou need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technology± Co., Ltd.